2018
A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma
Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecologic Oncology 2018, 149: 585-591. PMID: 29572027, PMCID: PMC5986604, DOI: 10.1016/j.ygyno.2018.03.050.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian carcinomaSerous ovarian carcinomaIL-6Ovarian cancerOvarian carcinomaE-cadHigh-grade serous ovarian adenocarcinomaEarly-stage ovarian cancerROC analysisEarly detectionMajority of patientsLethal gynecologic malignancyStage ovarian cancerOvarian cancer patientsBenign gynecologic pathologyNon-cancer controlsSerous ovarian adenocarcinomaEffective cancer screeningSerous ovarian cancerMultiple biomarker panelsFour-marker panelHigh differential gene expressionGynecologic malignanciesCA 125IL-1ra
2017
Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression
Menderes G, Bonazzoli E, Bellone S, Altwerger G, Black JD, Dugan K, Pettinella F, Masserdotti A, Riccio F, Bianchi A, Zammataro L, de Haydu C, Buza N, Hui P, Wong S, Huang GS, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecologic Oncology 2017, 147: 145-152. PMID: 28705408, PMCID: PMC5605415, DOI: 10.1016/j.ygyno.2017.07.009.Peer-Reviewed Original ResearchConceptsHigh HER2/neu expressionHER2/neu expressionEpithelial ovarian cancerHER2/neuAnti-tumor activityEOC cell linesT-DM1Neu expressionChemotherapy-resistant epithelial ovarian cancerLimited anti-tumor activityAntibody-dependent cell-mediated cytotoxicity (ADCC) activityCell linesSuperior anti-tumor activityCombination of trastuzumabLethal gynecologic malignancyEpithelial ovarian carcinomaTumor growth inhibitionEOC xenograftsGynecologic malignanciesPreclinical dataOvarian carcinomaOvarian cancerClinical studiesXenograft modelSingle agentSYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression
Menderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Masserdotti A, Pettinella F, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. Gynecologic Oncology 2017, 146: 179-186. PMID: 28473206, PMCID: PMC5533304, DOI: 10.1016/j.ygyno.2017.04.023.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAgedAnimalsAntibodies, Monoclonal, HumanizedAntibody-Dependent Cell CytotoxicityAntineoplastic Agents, AlkylatingBystander EffectCarcinoma, Ovarian EpithelialCell Line, TumorDuocarmycinsFemaleHumansImmunotoxinsIndolesMaytansineMiceMice, SCIDMiddle AgedNeoplasms, Glandular and EpithelialOvarian NeoplasmsPyrrolidinonesRandom AllocationReceptor, ErbB-2TrastuzumabXenograft Model Antitumor AssaysConceptsHER2/neu expressionAntibody-dependent cellular cytotoxicityEpithelial ovarian cancerLow HER2/neu expressionPeripheral blood lymphocytesHER2/neu 3Antibody-drug conjugatesT-DM1Neu expressionEOC cell linesNeu 3HER2-targeting antibody-drug conjugateNovel antibody-drug conjugateNovel HER2-targeting antibody-drug conjugateEpithelial ovarian carcinomaOvarian cancer xenograftsAnti-tumor activityCell linesEOC xenograftsTrastuzumab emtansineCancer xenograftsBlood lymphocytesOvarian cancerOvarian carcinomaSYD985
2006
Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice
Huang GS, Lopez-Barcons L, Freeze BS, Smith AB, Goldberg GL, Horwitz SB, McDaid HM. Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice. Clinical Cancer Research 2006, 12: 298-304. PMID: 16397055, PMCID: PMC4039036, DOI: 10.1158/1078-0432.ccr-05-0229.Peer-Reviewed Original ResearchMeSH KeywordsAlkanesAnimalsAntineoplastic Combined Chemotherapy ProtocolsCarbamatesCaspasesCell CycleCell Line, TumorDrug SynergismEnzyme ActivationFemaleHumansImmunohistochemistryLactonesMiceNeovascularization, PathologicOvarian NeoplasmsPaclitaxelPlatelet Endothelial Cell Adhesion Molecule-1PyronesXenograft Model Antitumor AssaysConceptsXenograft-bearing miceOvarian carcinomaTumor regressionCarcinoma cellsHuman ovarian cancer cellsOvarian carcinoma xenograftsOvarian cancer cellsCombination index methodOvarian carcinoma cellsCell cycle distributionTaxol efficacyCarcinoma xenograftsCD31 immunohistochemistryDrug combinationsImmunohistochemical analysisAnimal modelsSingle agentAntiangiogenic effectsLow dosesVivo modelNotable toxicityAntitumor efficacyDrug concentrationsCycle distributionMice
2004
Total laparoscopic hysterectomy for oncological indications with outcomes stratified by age
O'Hanlan KA, Huang GS, Lopez L, Garnier AC. Total laparoscopic hysterectomy for oncological indications with outcomes stratified by age. Gynecologic Oncology 2004, 95: 196-203. PMID: 15385132, DOI: 10.1016/j.ygyno.2004.07.023.Peer-Reviewed Original ResearchConceptsTotal laparoscopic hysterectomyBody mass indexOvarian carcinomaAdhesive bowel obstructionEarly ovarian carcinomaFamilial ovarian carcinomaMean blood lossOverall complication rateComplex pelvic massChi-square testUrologic complicationsBowel obstructionHospital stayComplication rateBlood lossCervical dysplasiaEndometrial neoplasiaLaparoscopic hysterectomyMass indexVaginal carcinomaPelvic massPreoperative diagnosisSurgical durationSurgical outcomesOncological indicationsSelective incorporation of total laparoscopic hysterectomy for adnexal pathology and body mass index
O'Hanlan KA, Huang GS, Lopez L, Garnier AC. Selective incorporation of total laparoscopic hysterectomy for adnexal pathology and body mass index. Gynecologic Oncology 2004, 93: 137-143. PMID: 15047227, DOI: 10.1016/j.ygyno.2003.12.020.Peer-Reviewed Original ResearchConceptsTotal laparoscopic hysterectomyBody mass indexAdnexal pathologyUrological injuriesLaparoscopic hysterectomyBMI groupsMass indexOvarian carcinomaExact testRecurrent breast cancerMean surgery durationMean complication rateFisher's exact testObstructive adhesionsEarly complicationsHospital stayStage IAChart abstractionComplication rateNodal yieldBlood lossOvarian pathologyMucinous cystadenomaPelvic massMean age
2003
Total Laparoscopic Hysterectomy
O'Hanlan K, Lopez L, Dibble S, Garnier A, Huang G, Leuchtenberger M. Total Laparoscopic Hysterectomy. Obstetrics And Gynecology 2003, 102: 1384-1392. DOI: 10.1097/00006250-200312000-00028.Peer-Reviewed Original ResearchTotal laparoscopic hysterectomyBody mass indexLaparoscopic hysterectomyBMI groupsHospital stayBlood lossComplication rateOccult ovarian carcinomaTotal complication rateShorter hospital stayMinor complication rateMinimal blood lossOverweight-25Urologic injuryAbdominal surgeryBMI categoriesInvasive hysterectomyLaparoscopic approachRetrospective reviewMass indexPatient seriesMean ageOvarian carcinomaMinimal operating timeBenign diagnosisTotal laparoscopic hysterectomy: body mass index and outcomes.
O'Hanlan KA, Lopez L, Dibble SL, Garnier AC, Huang GS, Leuchtenberger M. Total laparoscopic hysterectomy: body mass index and outcomes. Obstetrics And Gynecology 2003, 102: 1384-92. PMID: 14662231, DOI: 10.1016/j.obstetgynecol.2003.08.018.Peer-Reviewed Original ResearchConceptsTotal laparoscopic hysterectomyBody mass indexLaparoscopic hysterectomyBMI groupsHospital stayBlood lossComplication rateMass indexOccult ovarian carcinomaTotal complication rateShorter hospital stayMinor complication rateMinimal blood lossOperating timeOverweight-25Urologic injuryAbdominal surgeryBMI categoriesInvasive hysterectomyLaparoscopic approachPatient seriesRetrospective reviewMean ageOvarian carcinomaMinimal operating time